



EVA PHARMA



Company Profile

Innovation to
sustainable access.



Patient-centered end-to-end solutions:

**Sustain
access**

Develop

Innovate

**650 MAs in
60+ countries,**
including **32 EU countries,**
UK, Canada, Latin America,
Asia & Africa.
8 regional offices in
Germany, China, Egypt,
KSA, UAE, Kenya, Nigeria
& India.

**11 Different
dosage forms at
4 manufacturing
sites.**

**250 scientists at
2 research centers.**

5000 strong team.

**1,000,000
Packs
Daily**

Since 1917,

EVA Pharma has been dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access.

The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.

Our product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.

Our Mission is executed through three key areas of focus:



EVA Pharma
Medicines



Limitless
Naturals



Animal
Health

1917

Limitless Naturals:

Backed by science and trusted by healthcare professionals, Limitless Naturals offers food supplements that work with your body, not against it — helping you sleep deeper, move better, eat cleaner, and live stronger.

Limitless Naturals offers a wide range of advanced dosage forms — from gummies, sachets, effervescent powders, and chewables to oral dissolvable films (ODFs), and multilayered tablets — designed for superior absorption, ease of use, and a better consumer experience.



Animal Health:

Centered on supporting veterinarians in conquering their daily challenges, our high-quality animal health products, including vaccines, medicines, and feed additives, are meticulously crafted to meet international standards of excellence.

With our unwavering dedication to quality, innovation, and social impact, EVA Pharma Animal Health stands ready to fill crucial market gaps and promote the overall health and prosperity of our beloved animal companions.



Research & Development


EVA Pharma operates one of the largest and most advanced R&D and pharmaceutical development sites in the MENA region, offering end-to-end CDMO services.

Our technology-driven facility provides a fully integrated platform for drug product development.

Fully compliant with GMP and GLP guidelines and fully equipped R&D laboratories and a pilot area with the highest-rated machinery.


End-to-End Services:

Complete life cycle management from development, process optimization and scaling-up to commercial manufacturing.



mRNA Innovation Hub:

Our fully equipped research & development hub handles the complete mRNA vaccine development lifecycle - from digital sequencing to final drug formulation.



RNA
INNOVATION
HUB

Manufacturing Capabilities

Producing 1,000,000 packs daily.

Quality

EVA Pharma's state-of-the-art manufacturing facilities are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple global regulatory authorities.



EVA Pharma 6th of October Manufacturing Complex

125,000 sqm - 206 million medicines / year

Allows upscaling of manufacturing capabilities to produce different dosage forms: tablets, capsules, sachets, soft gelatin, a dedicated area for cephalosporins, carbapenems and a dedicated sterile filling area for biologics. The complex hosts a biologics' facility for human and animal therapeutics and vaccines. API manufacturing & animal house are under construction.



Haram Complex

114 million medicines / year

Produces different dosage forms such as vials, ampoules, sachets, tubes, capsules, tablets, syrups, creams, inhalation, BFS, patches (hydrogel & transdermal) and ODF.



10th of Ramadan Facility

12,000 sqm – 5.2 million medicines / year

First dedicated high - containment manufacturing site in the MENA region.



Limitless Naturals (6th of October)

3000 sqm - 26 million medicines / year

Produces a diverse portfolio of 95 supplements, including vitamins, minerals, antioxidants, and herbal products for both the domestic market and exports to over 24 countries worldwide.



EVA Pharma Research & Manufacturing Complex (Sudair, Saudi Arabia)

50,000 sqm - 990 million medicines / year

The industrial complex aims to become a center of gravity for pharmaceutical manufacturing in the region with an R & D center and five pharmaceutical factories, including: Immunosuppressants and oncology products, biologics, vaccines and a facility for oral dosage forms like DPIs, Bi-layer tablets, and ODT.



The Power of Collaboration

We believe the catalytic power of collaboration creates sustainable ventures. Our partnerships span the entire development spectrum, from API to finished product.

We offer flexible business models, from pure CMO to tech-transfer, co-developments or standard licensing. We empower our partners with comprehensive regulatory assistance, door - to - door logistics management, and investment in future pipeline projects, ensuring a thriving ecosystem of innovative solutions.



Sustainably supplying over
600 million doses to
CMO & out-licensing partners.

Out-licensing in 46 countries,
including 32 EU countries,
UK, Canada, Latin America,
Asia & Africa

70 ongoing contract
manufacturing projects
globally, including USA
& Canada

1

Out-Licensing

- EU-CTD Products
- Differentiated dosage forms
- FDF supply
- First to market generics

2

CDMO

Dedicated pilot area and diverse dosage forms including:

- DPI
- Patches
- Tablet
- Sachets
- BFS (Unidose)
- Multidose eye drops
- WFI
- Ampoule
- Vial
- Lyophilized
- Soft gelatin capsule
- Vaccine
- Insulins
- Cephalosporins

3


CMO

- Short lead time
- High quality
- Competitive prices
- Agile project team
- Flexible with high-free capacity

4

In-licensing

- Biosimilars
- mRNA technology
- Vaccines
- Hormones



Sustainable Impact:

We have a record of successful collaborations in a variety of areas, being a key provider of life - saving treatments for the most pressing health issues as HIV, HBV, HCV, COVID-19, as well as biologic treatments for diabetes in a list of low - to middle-income countries.

And today we are pioneering diverse medical solutions for the Middle East & Africa, through local manufacturing and tech-transfer collaborations.

A record of successful collaborations:

Metabolic health biologics:

As part of Lilly's 30x30 initiative, Eli Lilly and EVA Pharma are collaborating to deliver a sustainable supply of human and analogue insulin to people living with type 1 and type 2 diabetes in low- to middle-income countries.

Eli Lilly is supplying API along with technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in Africa.

In December 2024, Lilly and EVA Pharma announced regulatory approval and release of locally manufactured insulin Glargine in Egypt.



Localizing Innovative Anti-HIV Medicines:

EVA Pharma signed a non-exclusive, royalty-free voluntary licensing agreement with Gilead, allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product.

This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility to lenacapavir in 120 high-incidence, resource-limited countries.



EVA Pharma Signs Agreement with Gilead to Boost HIV Care in 120 Countries

RNA-based Vaccines and Therapeutics:

EVA Pharma, DNA Script, and Quantom Biosciences have signed MoU focusing on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source.

The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations.



Oncology Medications:

In collaboration with BeiGene, EVA Pharma to import, market, promote and distribute BeiGene's flagship Oncology medicines in Egypt.

By leveraging EVA Pharma's deep expertise in distribution, medical affairs, and regional market dynamics, this collaboration aims to make these innovative options more accessible to patients in Egypt.





**Innovation to
sustainable access.**



info@evapharma.com